Revenue: As of FY2025 Q3, the actual value is USD 136.56 M.

EPS: As of FY2025 Q3, the actual value is USD -0.14.

EBIT: As of FY2025 Q3, the actual value is USD -6.134 M.

Segment Revenue

• Consolidated Revenue: $136.6 million, a 36.7% increase from $99.9 million in Q3 2024.
• Fee-for-service Revenue: Grew by 13% over Q3 2024, driven by organic growth in Florida and Oregon.
• Retail Pharmacy and Dispensary Revenue: Contributed $75.9 million in revenue and $12.8 million in gross profit in Q3 2025.

Operational Metrics

• Gross Profit: $18.9 million, an increase of 31.7% from the previous year.
• Net Loss: $16.5 million compared to a net loss of $16.1 million in Q3 2024.
• Adjusted EBITDA: Improved to - $3.5 million from - $8.2 million in Q3 2024.

Cash Flow

• Cash and Cash Equivalents: $27.7 million as of September 30, 2025.
• Free Cash Flow: - $26.9 million for the nine months ended September 30, 2025, compared to - $29.4 million in the same period of 2024.

Unique Metrics

• Markets: Expanded to 22 markets from 14 in the previous year.
• Lives under Value-based Contracts: 1.9 million, unchanged from the previous year.

Outlook / Guidance

• The Oncology Institute updated its full-year 2025 revenue guidance to $495 to $505 million, up from the previous $460 to $480 million.
• Adjusted EBITDA guidance was revised to - $11 to - $13 million from the previous - $8 to - $17 million.
• The company expects Adjusted EBITDA of approximately $0 to $2 million in Q4 2025, assuming a stable global market environment.